Ciclofosfamida versus ifosfamida para niños y adultos jóvenes con sarcoma de tejidos blandos y óseo
Referencias
Referencias de los estudios excluidos de esta revisión
Baker KS, Anderson JR, Link MP, Grier HE, Qualman SJ, Maurer HM, et al. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV. Journal of Clinical Oncology 2000;18(12):2427‐34.
Bramwell VH, Mouridsen HT, Santoro A, Blackledge G, Somers R, Thomas D, et al. Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas. Cancer Chemotherapy and Pharmacology 1986;18(Suppl 2):S13‐6.
Bramwell VH, Mouridsen HT, Santoro A, Blackledge G, Somers R, Verwey J, et al. Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. European Journal of Cancer & Clinical Oncology 1987;23(3):311‐21.
Bramwell VH, Mouridsen HT, Santoro A, Blackledge G, Somers R, Verweij J, et al. Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft‐tissue sarcomas. The European Organization for Research and Treatment of Cancer (EORTC), Soft Tissue and Bone Sarcoma Group. Cancer Chemotherapy and Pharmacology 1993;31(Suppl 2):S180‐4.
Crist W, Anderson J, Maurer H, Wiener E, Donaldson S, Qualman S. Preliminary results for patients with local/regional tumors treated on the intergroup rhabdomyosarcoma study‐IV (1991‐97). ASCO Annual Meeting. 1999:[abstract 2141].
Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, et al. Intergroup rhabdomyosarcoma study ‐ IV: results for patients with nonmetastatic disease. Journal of Clinical Oncology 2001;19(12):3091‐102.
Dirksen U, Ranft A, Le Deley MC, Whelan J, Paulussen M, Oberlin O, et al. Comparison of Cyclophosphamide versus Ifosfamide containing adjuvant chemotherapy (CTX) in Ewing sarcoma (ES) patients: results of the randomized standard risk (SR) cohort of EUROE.‐E.W.I.N.G. 99 Trial. Journal of Cancer Research and Clinical Oncology 2012;138(Suppl 1):16 [abstract B31‐0218].
Dirksen U, van den Berg H, Le Delay M, Whelan J, Oberlin O, Paulussen M, et al. Impact of gender on efficacy of alkylating agents and their acute toxicity in patients with standard risk localized ewing sarcomas (EWS) in the EURO‐EWING99‐(EE99)‐R1 trial. Pediatric Blood and Cancer 2013;60:26 [abstract O‐0093].
Dunst J, Ahrens S, Paulussen M, Rübe C, Winkelmann W, Zoubek A, et al. Second malignancies after treatment for Ewing's sarcoma: a report of the CESS‐studies. International Journal of Radiation Oncology, Biology, Physics 1998;42(2):379‐84.
Gaspar N, Rey A, Bérard PM, Michon J, Gentet JC, Tabone MD, et al. Risk adapted chemotherapy for localised Ewing's sarcoma of bone: the French EW93 study. European Journal of Cancer 2012;48:1376‐85.
Gupta AA, Anderson JR, Pappo AS, Spunt SL, Dasgupta R, Indelicato DJ, et al. Patterns of chemotherapy‐induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee. Cancer 2012;118:1130‐37.
Jurgens H, Ahrens S, Frohlich B, Paulussen M, Zoubek A, Lewis I, et al. European Intergroup Cooperative Ewing's Sarcoma Study (EICESS92): first results. ASCO Annual Meeting. 2000:[abstract 2286].
Le Deley MC, Paulussen M, Lewis I, Brennan B, Ranft A, Whelan J, et al. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard‐risk Ewing sarcoma: results of the randomized noninferiority Euro‐EWING99‐R1 trial. Journal of Clinical Oncology 2014;32:2440‐48.
Paulussen M, Ahrens S, Braun‐Munzinger G, Craft AW, Dockhorn‐Dworniczak B, Dörffel W, et al. EICESS 92 (European Intergroup Cooperative Ewing's Sarcoma Study) ‐ preliminary results. Klinische Padiatrie 1999;211(4):276‐83.
Paulussen M, Ahrens S, Lehnert M, Taeger D, Hense HW, Wagner A, et al. Second malignancies after Ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study. Annals of Oncology 2001;12(11):1619‐30.
Paulussen M, Craft AW, Lewis I, Hackshaw A, Douglas C, Dunst J, et al. Results of the EICESS‐92 Study: two randomized trials of Ewing's sarcoma treatment‐cyclophosphamide compared with ifosfamide in standard‐risk patients and assessment of benefit of etoposide added to standard treatment in high‐risk patients. Journal of Clinical Oncology 2008;26(27):4385‐93.
Ridola V, Fawaz O, Aubier F, Bergeron C, de Vathaire F, Pichon F, et al. Testicular function of survivors of childhood cancer: a comparative study between ifosfamide‐ and cyclophosphamide‐based regimens. European Journal of Cancer 2009;45(5):814‐8.
Stevens MC, Rey A, Bouvet N, Ellershaw C, Flamant F, Habrand JL, et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology ‐ SIOP Malignant Mesenchymal Tumor 89. Journal of Clinical Oncology 2005;23(12):2618‐28.
Van den Berg H, Paulussen M, Gaspar N, Lewis I, Dirksen U, Brennan B, et al. Impact of gender on efficacy and acute toxicity in standard risk localized (SR) Ewing sarcomas (ES) in the Euro‐Ewing99‐R1 trial. Journal of Clinical Oncology 2013;31(15 Suppl):10031.
Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purfürst C, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS‐82) with salvage chemotherapy based on histological tumor response. Journal of Clinical Oncology 1988;6(2):329‐37.
Referencias adicionales
Burke GA, Estlin EJ, Lowis SP. The role of pharmacokinetic and pharmacodynamic studies in the planning of protocols for the treatment of childhood cancer. Cancer Treatment Reviews 1999;25:13‐27.
Carli M, Passone E, Perilongo G, Bisogno G. Ifosfamide in pediatric solid tumors. Oncology 2003;65(Suppl 2):99‐104.
Fawaz O, Ridola V, Schmitt C, Gentet JC, Aubier F, Orbach D, et al. Ifosfamide vs. cyclophosphamide: long term gonadal effects in male survivors of childhood cancer. Sarcoma 2005;9:61.
German Childhood Cancer Registry: Annual Report 2004. http://www.kinderkrebsregister.de/texte04pdf/6_22.pdf (accessed 15 December 2005).
German Childhood Cancer Registry: Annual Report 2004 Appendix. http://www.kinderkrebsregister.de/texte04pdf/taba1te2.pdf (accessed 15 December 2005).
Groninger E, Proost JH, De Graaf SSN. Pharmacokinetic studies in children with cancer. Critical Reviews in Oncology/Hematology 2004;52:173‐97.
Higgins J, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. The Cochrane Collaboration 2005. http://www.cochrane.org/resources/handbook/hbook.htm.
Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org.
Howell SJ, Shalet SM. Testicular function following chemotherapy. Human Reproduction Update 2001;7:363‐9.
Kasper B, Ho AD, Egerer G. Is there an indication for high‐dose chemotherapy in the treatment of bone and soft‐tissue sarcoma?. Oncology 2005;68:115‐21.
Knijnenburg SL, Mulder RL, Schouten‐Van Meeteren AYN, Bökenkamp A, Blufpand H, vanDulmen‐den Broeder E, et al. Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer. Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD008944.pub2]
Lai KN, Tang SC, Mok CC. Treatment for lupus nephritis: a revisit. Nephrology (Carlton) 2005;10:180‐8.
Paulussen M, Ahrens S, Dunst J, Winkelmann W, Exner GU, Kotz R, et al. Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. Journal of Clinical Oncology 2001;19:1818‐29.
Raney B, Ensign LG, Foreman J, Khan F, Newton W, Ortega J, et al. Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor. American Journal of Pediatric Hematology/Oncology 1994;16:286‐95.
Rossi R, Kleta R, Ehrich JH. Renal involvement in children with malignancies. Pediatric Nephrology 1999;13:153‐62.
Shaw PJ, Eden T. Ifosfamide in paediatric oncology: tried but not tested?. Lancet 1990;335:1022‐3.
Simbre VC, Duffy SA, Dadlani GH, Miller TL, Lipshultz SE. Cardiotoxicity of cancer chemotherapy: implications for children. Paediatric Drugs 2005;7:187‐202.
Skinner R. Chronic ifosfamide nephrotoxicity in children. Medical and Pediatric Oncology 2003;41:190‐7.
Spunt SL, Smith LM, Ruymann FB, Qualman SJ, Donaldson SS, Rodeberg DA, et al. Cyclophosphamide dose intensification during induction therapy for intermediate‐risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group. Clinical Cancer Research 2004;10:6072‐9.
Stöhr W, Patzer L, Paulides M, Kremers A, Beck JD, Langer T, et al. Growth impairment after ifosfamide‐induced nephrotoxicity in children. Pediatric Blood and Cancer 2007;48:571‐6.
Van den Berg H. Biology and therapy of malignant solid tumors in childhood. Cancer Chemotherapy and Biological Response Modifiers 2002;20:605‐25.
Weller F, Huppertz HI. The treatment of juvenile rheumatism: pharmacotherapy [Die Behandlung des kindlichen Rheumas: Pharmakotherapie]. Zeitschrift fur Rheumatologie 2005;64:308‐16.
Zhang J, Tian Q, Chan SY, Duan W, Zhou S. Insights into oxazaphosphorine resistance and possible approaches to its circumvention. Drug Resistance Updates 2005;8:271‐97.
Referencias de otras versiones publicadas de esta revisión
Mulder RL, Paulides M, Langer T, Kremer LCM, van Dalen EC. Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. Cochrane Database of Systematic Reviews 2010, Issue 2. [DOI: 10.1002/14651858.CD006300.pub2]
Mulder RL, Paulides M, Langer T, Kremer LCM, van Dalen EC. Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD006300]
Paulides M, Stöhr W, Langer T, Kremer LCM, van Dalen EC. Cyclophosphamide versus ifosfamide for paediatric and young adult sarcoma patients. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD006300. [DOI: 10.1002/14651858.CD006300]
Characteristics of studies
Characteristics of excluded studies [ordered by study ID]
| Study | Reason for exclusion |
| Preliminary results of Crist 2001 | |
| Preliminary results of Bramwell 1987 | |
| Included patients aged 30 years or older; no separate data on patients less than 30 years of age | |
| Same study as Bramwell 1986 and Bramwell 1987 | |
| Conference proceeding of Crist 2001 | |
| All patients received cyclophosphamide during continuation therapy; no data until continuation therapy presented separately for both treatment groups | |
| All patients received ifosfamide during induction therapy | |
| All patients received ifosfamide during induction therapy | |
| No randomisation of participants to cyclophosphamide versus ifosfamide; historical controls | |
| Not an RCT/CCT; all patients received cyclophosphamide | |
| All patients received cyclophosphamide during continuation therapy; no survival data until continuation therapy presented separately for both treatment groups | |
| Conference proceeding of Paulussen 2001a | |
| All patients received ifosfamide during induction therapy | |
| Same study as Paulussen 2001a | |
| Included patients aged 30 years or older; no separate data on patients less than 30 years of age; all patients received ifosfamide | |
| Same study as Paulussen 2001a | |
| Historical controls; other chemotherapy not the same in both treatment groups; no data on only sarcoma patients; primary outcome not described Also presented as a conference proceeding (Fawaz 2005) | |
| Not an RCT/CCT; none of the patients received cyclophosphamide | |
| All patients received ifosfamide during induction therapy | |
| No randomisation of participants to cyclophosphamide versus ifosfamide |
RCT: randomised controlled trial; CCT: controlled clinical trial
